Health Catalyst (HCAT) Reports Q4 Earnings: What Key Metrics Have to Say

Core Insights - Health Catalyst (HCAT) reported revenue of $74.68 million for the quarter ended December 2025, reflecting a year-over-year decline of 6.2% while EPS increased to $0.08 from $0.04 a year ago [1] - The reported revenue exceeded the Zacks Consensus Estimate of $73.61 million, resulting in a surprise of +1.45%, although the EPS fell short of the consensus estimate of $0.09 by -14.26% [1] Revenue Breakdown - Professional services revenue was $22.81 million, slightly below the estimated $22.88 million, marking an 18.6% decline compared to the same quarter last year [4] - Technology revenue reached $51.87 million, surpassing the estimated $50.74 million, with a modest year-over-year increase of 0.5% [4] Profit Metrics - Adjusted Gross Profit for Professional Services was $4.61 million, slightly below the average estimate of $4.68 million [4] - Adjusted Gross Profit for Technology was $35.35 million, exceeding the estimated $34.51 million [4] Stock Performance - Over the past month, shares of Health Catalyst have returned -6.5%, compared to a -2.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3]